Peak Bio Past Earnings Performance
Past criteria checks 0/6
Peak Bio's earnings have been declining at an average annual rate of -157.1%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 4.6% per year.
Key information
-157.1%
Earnings growth rate
-190.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -4.6% |
| Return on equity | n/a |
| Net Margin | -4,528.1% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Peak Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -21 | 11 | 0 |
| 31 Mar 23 | 1 | -18 | 11 | 0 |
| 31 Dec 22 | 1 | -13 | 9 | 0 |
| 30 Sep 22 | 0 | -8 | 4 | 0 |
| 30 Jun 22 | 0 | -8 | 4 | 0 |
| 31 Mar 22 | 1 | -8 | 3 | 0 |
| 31 Dec 21 | 1 | -8 | 2 | 0 |
Quality Earnings: PKBO is currently unprofitable.
Growing Profit Margin: PKBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PKBO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PKBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PKBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: PKBO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.